CLINICAL TRIALS AND OBSERVATIONS Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

1Department of Nuclear Medicine, University of Cologne, Cologne, Germany; 2German Hodgkin Study Group, University of Cologne, Cologne, Germany; 3Department of Clinical Hematology, Third Faculty of Medicine, Charles University, Prague, Czech Republic; 4Schweizer Arbeitsgruppe für Klinische Krebsforschung, Bern, Switzerland; 5Klinik für Strahlenheilkunde, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany; 6Department of Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 7Department of Nuclear Medicine, Hanover University Medical School, Hanover, Germany; 8Department of Hematology, VU University Medical Centre, Amsterdam, The Netherlands; 9Department of Nuclear Medicine, University of Duisburg-Essen, Essen, Germany; 10Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany; 11Department of Nuclear Medicine, University of Wuerzburg, Wuerzburg, Germany; 12Department of Nuclear Medicine, Gutenberg University Hospital, Mainz, Germany; 13Department of Nuclear Medicine, University of Tuebingen, Tuebingen, Germany; 14Department of Radiation Oncology, University of Cologne, Cologne, Germany; and 15Department I of Internal Medicine, University of Cologne, Cologne, Germany